AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (L

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. IONS
3. AZN
4. SPY
5. NVDA
6. DKNG
7. BSX
8. ODFL
9. ACN
10. USO

Go back to AbbVie Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Large B-Cell Lymphoma (L
AbbVie (NYSE: ABBV) Delayed: 256.46 --0 (-0%)
Previous Close $256.46    52 Week High $68.12 
Open $256.46    52 Week Low $50.71 
Day High $256.46    P/E 55.63 
Day Low $256.46    EPS $4.61 
Volume 440,094